NCT05671445

The Study of CM326 in Adult Subjects With Atopic Dermatitis

An Open, Multineutral Study Evaluating the Safety and Efficacy of CM326 in the Long-term Treatment of Adult Subjects With Atopic Dermatitis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Keymed Biosciences Co.Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a open-label, multi-center study to evaluate the safety and efficacy of CM326 in atopic adrmatitis subjects.

Detailed description

The study consists of 3 periods, a up-to-4-week Screening Period, a 52-week Treatment Period and a 8-week Safety Follow-up Period.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
BIOLOGICAL	CM326	CM326 injection

Timeline

• Start date: 2023-02-09
• Primary completion: 2024-03-28
• Completion: 2025-03-28
• First posted: 2023-01-04
• Last updated: 2023-08-01

Locations

1 site across 1 country: China